Literature DB >> 6507457

Long-term antiarrhythmic therapy. Problem of low drug levels and patient noncompliance.

A Squire, M E Goldman, J Kupersmith, E H Stern, V Fuster, P Schweitzer.   

Abstract

Maintenance of adequate serum blood levels is crucial to successful antiarrhythmic therapy. Serum levels of four antiarrhythmic agents (long-acting procainamide, quinidine sulfate, quinidine gluconate, and disopyramide) were determined in 98 consecutive ambulatory patients receiving long-term oral therapy. Medication dosages, dosing intervals, and time elapsed from last dosage until blood sampling were determined. Seventy-five patients (76.5 percent) had subtherapeutic blood levels (with mean levels less than 50 percent of the suggested minimum), and only 22 patients (22.5 percent) had therapeutic levels. Even among the 61 patients who claimed to have taken their medications within the six hours prior to blood sampling, 43 (70 percent) had subtherapeutic levels. These ratios held among all subgroups studied. Physicians should be aware of the high proportion of patients receiving long-term oral antiarrhythmic therapy with inadequate serum blood levels when planning therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6507457     DOI: 10.1016/0002-9343(84)90184-0

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  7 in total

1.  Absorption kinetics of oral sotalol combined with cisapride and sublingual sotalol in healthy subjects.

Authors:  V H Deneer; L Lie-A-Huen; J H Kingma; J H Proost; J C Kelder; J R Brouwers
Journal:  Br J Clin Pharmacol       Date:  1998-05       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring of antiarrhythmic drugs. Rationale and current status.

Authors:  R Latini; A P Maggioni; A Cavalli
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 3.  Causes and problems of nonresponse or poor response to drugs.

Authors:  P Salvà Lacombe; J A García Vicente; J Costa Pagès; P Lucio Morselli
Journal:  Drugs       Date:  1996-04       Impact factor: 9.546

4.  Use of antiarrhythmic drug therapy and clinical outcomes in older patients with concomitant atrial fibrillation and coronary artery disease.

Authors:  Benjamin A Steinberg; Samuel H Broderick; Renato D Lopes; Linda K Shaw; Kevin L Thomas; Tracy A DeWald; James P Daubert; Eric D Peterson; Christopher B Granger; Jonathan P Piccini
Journal:  Europace       Date:  2014-04-21       Impact factor: 5.214

5.  BW A256C, a chemically novel class 1 antiarrhythmic agent. A comparison of in vitro and in vivo activity with other class 1 antiarrhythmic agents.

Authors:  G Allan; S Donoghue; M J Follenfant; D A Sawyer
Journal:  Br J Pharmacol       Date:  1986-06       Impact factor: 8.739

6.  Gaps in cardiovascular medication taking: the tip of the iceberg.

Authors:  P Rudd; J Ramesh; C Bryant-Kosling; D Guerrero
Journal:  J Gen Intern Med       Date:  1993-12       Impact factor: 5.128

Review 7.  Atrial Fibrillation in Inherited Channelopathies.

Authors:  Baha'a Al-Azaam; Dawood Darbar
Journal:  Card Electrophysiol Clin       Date:  2021-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.